Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

Nscale files for New York at $14.6bn

4 min read
16:30UTC

Nscale lodged its Form S-1 on 18 September, asking American public markets to price $103.4 billion of contracted deals against revenue of just over $100 million a quarter.

TechnologyDeveloping
Key takeaway

Nscale will be priced in public on contracted promises rather than delivered revenue.

Nscale, the London artificial intelligence infrastructure company, filed a Form S-1 with the Securities and Exchange Commission (the SEC, the United States markets regulator) on 18 September, seeking the ticker NSCL on the New York Stock Exchange (NYSE)⁠1. An S-1 is the registration statement a company must lodge before selling shares to the American public. The filing carries the $14.6 billion valuation set by Nscale's March 2026 Series C, a private funding round lettered by stage. Goldman Sachs, JPMorgan and Morgan Stanley are leading the offering, and the banks have not disclosed terms⁠2.

Two numbers in the filing sit awkwardly together. Nscale reports a contracted order book, meaning customer contracts for future revenue at agreed terms, worth $103.4 billion. Its trading revenue runs at a little over $100 million each quarter⁠3. The order book is therefore worth roughly a thousand quarters of trading at the present rate.

For the six months to June the company reported $140.6 million of revenue, up from $10.4 million a year earlier, alongside a net loss of $1.02 billion, widened from a $368.9 million loss in the same period of 2025. More than half of that first-half revenue came from a single customer the filing does not name. A loss seven times revenue is ordinary for a business pouring concrete and buying graphics processors. A revenue line resting on one buyer is a different kind of exposure, and a public shareholder inherits the risk of one contract renegotiation.

Two details in the primary record have not reached the trade coverage. EDGAR, the SEC's public filing database, records the S-1 as lodged on 18 September, three days before the trade press wrote it up, and the registrant, NSCALE Ltd, was renamed from DSNS HOLDINGS Ltd on 17 February 2026⁠4. Ordinary pre-listing housekeeping, and worth knowing before the prospectus lands.

British semiconductor exits hit a five-year low this summer with no flotation at all, and the listing window that would have carried a company of this size onto the London market has not opened. Nscale is also the third British artificial intelligence company in three months to be priced on contracted commitments rather than delivered revenue, after Humanoid's industrial orders and CuspAI's coalition of 45 partners. Those two were priced by a handful of investors behind closed doors. This one will be priced by anyone with a brokerage account. Nvidia and Aker ASA hold stock from earlier rounds, and neither is obliged to buy at the listing price.

Deep Analysis

In plain English

Nscale is a British company that rents out computing power used to train and run AI systems. It has asked US regulators for permission to sell shares to the public on the New York Stock Exchange rather than in London. The company says customers have signed contracts worth $103.4bn of future business, but its actual sales each quarter are only just over $100m. That gap between promised future business and money already earned is the central question any buyer of the shares has to weigh.

Deep Analysis
Root Causes

Nscale's capital need is the root constraint: building GPU data centre capacity at the scale implied by a $103.4bn order book requires financing far beyond what a single UK growth round can supply, pushing the company toward the deepest available pool of specialist AI-infrastructure capital.

That pool sits overwhelmingly in New York. The Treasury's own Mansion House Compact, signed in 2023, exists because UK defined contribution pension funds had cut their domestic equity allocation to a fraction of historic levels, thinning the pool of UK institutional money able to underwrite a British company's public listing at this scale.

What could happen next?
  • Precedent

    A well-received listing would reinforce New York, not London, as the default venue for British-founded AI infrastructure companies raising growth capital.

  • Risk

    If contracted customers scale back capacity commitments before they convert to revenue, the valuation gap between the order book and trailing sales becomes a post-listing volatility risk, as it did for CoreWeave in 2025.

First Reported In

Update #15 · Nscale takes $103.4bn of contracts to NYSE

Tech Funding News· 21 Sept 2026
Read original →
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.